Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LAGλ-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma

1 Jun 2006

Abstract excerpt

We set out to generate new human myeloma tumors that grow in immunodeficient mice and can be used for pathophysiological studies and rapid evaluation of new therapies. Fresh whole core bone marrow (BM) biopsies taken from 33 myeloma patients were engrafted into the hind limb muscle of severe combined immunodeficient (SCID) mice. Human Ig was detected in 28/33 mice and three grew palpable tumors displaying many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16685443
DOI: 10.3892/ijo.28.6.1409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LAGλ-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myelomaPMID 16685443Read ↗

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.Semantic proximity Read ↗

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myelomaSemantic proximity Read ↗

UCHL1is a biomarker of aggressive multiple myeloma required for disease progressionSemantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

Immune-mediated tumor control in the 5TGM1 transfer model of multiple myelomaSemantic proximity Read ↗

The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cellsSemantic proximity Read ↗

A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple MyelomaSemantic proximity Read ↗

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradationSemantic proximity Read ↗

NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.Semantic proximity Read ↗

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro , Ex Vivo , and In Vivo in the 5T33MM Mouse ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.